GLP1R and chronic kidney disease: Similar trends have been shown in real-word studies of patients with diabetes and CKD, where African American race was associated with lower use of SGLT-2is and GLP-1 RAs, higher use of sulfonylureas, and higher rates of hypoglycemia [73,74].